{"nctId":"NCT00772031","briefTitle":"NINDS CRC Chronic Migraine Treatment Trial","startDateStruct":{"date":"2008-10"},"conditions":["Chronic Migraine"],"count":191,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: propranolol LA","Drug: topiramate"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: topiramate","Drug: placebo"]}],"interventions":[{"name":"propranolol LA","otherNames":["Inderal LA"]},{"name":"topiramate","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of chronic migraine for at least 6 months\n* Age â‰¥ 18 years and age of migraine onset 60 or younger\n* EKG performed in the last 12 months\n\nExclusion Criteria:\n\n* Prior neuro-imaging suggesting secondary structural causes of headache\n* Beck Depression Inventory FastScreen score of 13 or greater or other severe psychiatric disorder\n* Contraindication to or prior intolerance of topiramate or propranolol (no history of sinus bradycardia, heart block, heart failure, diabetes prone to hypoglycemia, asthma, kidney stones)\n* History of kidney failure or nephrolithiasis\n* A female who is currently pregnant or lactating or planning to become pregnant in the next year, or is of child-bearing potential and not practicing an acceptable form of birth control\n* Currently requires butalbital or opioid drugs for acute headache treatment 10 or more days a month\n* Failure of prior trials with at least 50 mg of topiramate combined with at least 80 mg of propranolol\n* Use of other migraine preventive drugs (Medications graded as groups 1, 2, 3, and 4 in the AAN Evidence-based Guideline: valproate, divalproex sodium, gabapentin, amitriptyline, nortriptyline, protriptyline, beta-blocker, calcium channel blocker, cyproheptadine; and tizanidine) within the last two months or has received botulinum toxin injection in the past 3 months","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline","description":"(Number of moderate to severe headache days (as defined by the International Headache Society Guidelines (2006)) counted over a 28 day diary period at baseline (before treatment with propranolol or placebo)) minus (the number of moderate to severe headache days counted over a 56 day diary period (weeks 16-24 post treatment) divided by 2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"5.98"},{"groupId":"OG001","value":"4.7","spread":"5.66"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Beck's Depression Inventory FastScreen Score at 6 Months","description":"Total score from Beck's Depression Inventory FastScreen at 6 months minus total score from Beck's Depression Inventory FastScreen at baseline. Scale scores range from 0 to 21 with higher values indicating worsening depression. the following categories separate participants into groups of depression levels: Minimal (Score 0-3), Mild (Score 4-8),Moderate (Score 9-12),Severe (Score 13-21).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.25"},{"groupId":"OG001","value":"0.6","spread":"0.30"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Migraine Disability Assessment (MIDAS) Score at 6 Months","description":"MIDAS scoring ranges from 0 to 270. The scores are divided into ranges of disability with higher scores indicating increased disability as follows: 0-5 (Grade I - Minimal or infrequent disability); 6-10 (Grade II - Mild or infrequent disability); 11-20 (Grade III - Moderate disability); and 21+ (Grade IV - Severe disability).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":"3.70"},{"groupId":"OG001","value":"-3.46","spread":"3.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Migraine Specific Quality of Life (MSQ)-Role Restrictive Score at 6 Months","description":"The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"5.5"},{"groupId":"OG001","value":"-2.2","spread":"5.71"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Migraine-Specific Quality of Life (MSQ)-Role Preventive at 6 Months","description":"The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":"2.88"},{"groupId":"OG001","value":"5.9","spread":"3.10"},{"groupId":"OG002","value":"-11.5","spread":"5.00"},{"groupId":"OG003","value":"11.0","spread":"5.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Migraine-Specific Quality of Life (MSQ) - Emotional Function at 6 Months","description":"The MSQ (version 2.1 copyrighted 1992, 1996, 1998 by Glaxo Wellcome Inc., Research Triangle Park, North Carolina) is a 14 item questionnaire. Item responses are summed and scored as a total score and three domains: Role Preventive, Role Restrictive, Emotional Function. Scores within each domain are rescaled to range from 0 to 100. A lower score indicates a poorer quality of life associated with that domain or in total. Because of the observed interaction within a domain, only domain scores were used as outcome measures for this study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.9","spread":"3.43"},{"groupId":"OG001","value":"9.8","spread":"3.80"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":96},"commonTop":["Fatigue","Paraesthesia","Mental Impairment","Dizziness","Memory Impairment"]}}}